However, unlike CML which is driven solely by the BCR-ABL oncogene, most blood cancers are more genetically heterogeneous displaying complex clonal architecture with conventional chemotherapeutic agents remaining the backbone of most therapy regimens. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.